1-4 of 4
Teemu T. Junttila
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody

Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh, Teemu T. Junttila
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6447–6458.
https://doi.org/10.1158/1078-0432.CCR-18-1139
Published: 13 December 2018
View article titled, IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody
Open the PDF for IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody in another window
Includes: Supplementary data
Journal Articles

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Na Zhang, Mika Savisalo, Pekka Mali, Jarmo Kulmala, Jaakko Pulkkinen, Reidar Grenman, Klaus Elenius
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 4103–4111.
https://doi.org/10.1158/1078-0432.CCR-05-2404
Published: 03 July 2006
View article titled, Signaling via ErbB2 and ErbB3 Associates with Resistance and <em>Epidermal Growth Factor Receptor</em> (<em>EGFR</em>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
Open the PDF for Signaling via ErbB2 and ErbB3 Associates with Resistance and <em>Epidermal Growth Factor Receptor</em> (<em>EGFR</em>) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells in another window
Journal Articles

Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients

Teemu T. Junttila, Matti Laato, Tero Vahlberg, Karl-Ove Söderström, Tapio Visakorpi, Jorma Isola, Klaus Elenius
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5346–5357.
Published: 12 November 2003
View article titled, Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: <subtitle>Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients</subtitle>
Open the PDF for Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: <subtitle>Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients</subtitle> in another window
Journal Articles

ERBB Receptor Signaling Promotes Ependymoma Cell Proliferation and Represents a Potential Novel Therapeutic Target for This Disease

Richard J. Gilbertson, Lyndsay Bentley, Roberto Hernan, Teemu T. Junttila, Adrian J. Frank, Hannu Haapasalo, Michele Connelly, Cynthia Wetmore, Tom Curran, Klaus Elenius, David W. Ellison
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (10): 3054–3064.
Published: 01 October 2002
View article titled, ERBB Receptor Signaling Promotes Ependymoma Cell Proliferation and Represents a Potential Novel Therapeutic Target for This Disease
Open the PDF for ERBB Receptor Signaling Promotes Ependymoma Cell Proliferation and Represents a Potential Novel Therapeutic Target for This Disease in another window